FarEye Launches Grow – A Game-changing Self-Serve Merchant Portal for Logistics Companies to Accelerate Customer Acquisition and Drive Growth
11.5.2023 17:00:00 EEST | Business Wire | Press release
FarEye today announced Grow, a solution for logistic companies to provide a modern-age experience to its customers. With a user-friendly interface, frictionless onboarding, automated booking, and seamless payments integration, Grow is set to empower logistics businesses to accelerate customer acquisition, improve customer satisfaction, and drive growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230511005538/en/
Grow is a cutting-edge self-serve merchant portal designed to revolutionize the way logistics companies manage their shipping operations. (Photo: Business Wire)
With the parcel delivery market projected to hit $200 billion by 2026 and over tens of millions of shippers worldwide, it's clear that logistic companies have an unprecedented opportunity for growth. Every retailer and e-commerce company wants to offer home delivery but continues to struggle to find the right, modern-age logistics partner and are stuck with legacy ways of home delivery. Grow enables logistics companies to address this demand-supply gap.
"We are thrilled to launch Grow, which we believe will become an indispensable tool for logistics companies seeking to acquire new retailers and stay ahead of the competition," said Kushal Nahata, CEO of FarEye. "Our team has worked tirelessly to create a platform that unlocks the potential of thousands of logistic companies, and we are confident that Grow will transform the way logistics businesses interact with their customers and manage their day-to-day operations."
FarEye Grow is an easy way for merchants to self-serve, get quotes, create orders, generate labels, and manage transactions. It also offers shipment-level visibility and in-built exception management, enabling retailers and shippers to save time and effort, leading to increased customer satisfaction. In addition, automated invoice generation and payments with digital wallet capabilities allow logistic companies to reduce payment delays and improve cash flow. Grow is equipped with built-in plug-ins with major e-commerce platforms like Shopify and BigCommerce, allowing shippers to connect and start delivering quickly.
FarEye Grow is a part of the FarEye product portfolio that supports companies through the complete order-to-door delivery journey. It has products like Ship, Track, Route, Execute, Experience, Analyze, and now, Grow, which offers the following key benefits:
- Personalized portal for easy onboarding: Allows self-onboarding and complete order entry, get quotes, generate labels, real-time status updates, and proof of delivery on one platform.
- Track and trace visibility: Provides real-time track and trace visibility and address validation to merchants for booked orders.
- Scale with your merchants: Track merchants’ growth, run campaigns based on orders and transactions, and make recommendations for merchants to transact more for revenue and business growth.
- Booking order transparency: Self-service merchant order booking directly from the platform, this helps CEPs track revenue and reduce lost revenue.
- Digital wallet management: Offer customers purchase credit for their shipping needs. Provide complete visibility into all transactions, book and pay for shipments by multiple payment modes, including directly by wallet.
FarEye's Grow is the ultimate customer portal for CEP companies looking to streamline shipping operations, expand their customer network, and achieve sustainable growth in today's competitive industry. To learn more about the portal and how it can benefit your business, visit the FarEye website today.
About FarEye
FarEye’s Delivery Management platform turns deliveries into a competitive advantage. Retail, e-commerce and third-party logistics companies use FarEye’s unique combination of orchestration, real-time visibility, and branded customer experiences to simplify complex last-mile delivery logistics. The FarEye platform allows businesses to increase consumer loyalty and satisfaction, reduce costs and improve operational efficiencies. FarEye has 150+ customers across 30 countries and five offices globally. FarEye, First Choice for Last Mile.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005538/en/
Contact information
PR Contact:
Bradford Peirce, Industry Strategy Executive, bradford.peirce@fareye.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release
The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv
Seiden Law LLP States: Cambodian Businessman Leak Yim, Wrongfully Accused in Thailand, Seeks Redress in U.S. Court29.6.2026 07:00:00 EEST | Press release
Seiden Law LLP (“Seiden Law”), legal counsel for Mr. Leak Yim, a Cambodia national, and his family, announces the filing of an application in U.S. federal district court in Washington D.C., seeking court-ordered discovery to uncover the false and misleading information that may have led to mistaken prosecution in Thailand of Mr. Yim as well as his unwarranted identification to Congress as being associated with scam centers in Asia. 28 U.S.C. § 1782 (“1782”) provides powerful evidence-gathering remedies, permitting an applicant to obtain evidence in the United States to assist international proceedings. Seiden Law, a U.S. law firm with significant experience in 1782 cases, has filed this application to compel production of documents and sworn testimony from persons in the U.S. that will shed light on the circumstances surrounding recent actions against Mr. Yim. “Mr. Yim and his young family are the apparent victims of guilt by association and political persecution,” said Robert Seiden,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom